Literature DB >> 8721560

Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals.

F Biron1, F Lucht, D Peyramond, A Fresard, T Vallet, F Nugier, J Grange, S Malley, F Hamedi-Sangsari, J Vila.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8721560     DOI： 10.1016/0166-3542(95)00931-0

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  8 in total

Review 1.  Didanosine: an updated review of its use in HIV infection.

Authors:  C M Perry; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.

Authors:  E Ravot; J Lisziewicz; F Lori
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.

Authors:  D De Forni; M R Stevens; F Lori
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.

Authors:  S Palmer; R W Shafer; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate.

Authors:  J G Julias; V K Pathak
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.

Authors:  Louis M Mansky; Dennis K Pearl; Lisa C Gajary
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.

Authors:  Louis M Mansky; Erwann Le Rouzic; Serge Benichou; Lisa C Gajary
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

8.  VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

Authors:  Franco Lori; Davide De Forni; Elly Katabira; Denis Baev; Renato Maserati; Sandra A Calarota; Pedro Cahn; Marco Testori; Aza Rakhmanova; Michael R Stevens
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.